P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases
Silvio Danese(IRCCS Ospedale San Raffaele), Bram Verstockt(KU Leuven), Séverine Vermeire(KU Leuven), M Dubinsky, Britta Siegmund(Humboldt-Universität zu Berlin), Andrés Yarur(Cedars-Sinai Medical Center), Fabio Cataldi(Pfizer (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Brian G. Feagan(Western University), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), J F Colombel(European CanCer Organisation), Remo Panaccione(University of Calgary), Rebecca Mosig, Florian Rieder(Cleveland Clinic)
Cited by 3
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k